// App-Quantinova.ai

: Combining Parthenolide and Sulfasalazine Improves Toxicity to CD200+ LIC Populations in Childhood ALL

Researchers

Presenter

  • Paraskevi Diamanti

Principal Investigators

  • Anas Al-Masri

  • Benjamin C Ede

  • Allison Blair

Medical Centers

  • Bristol Institute for Transfusion Sciences, NHS Blood and Transplant, Bristol, United Kingdom

  • University of Bristol, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Annexin V

  • Cluster of Differentiation 19

  • Cluster of Differentiation 34

  • Proto-oncogene tyrosine-protein kinase ROS

  • Mesenchymal stem cells

Drug/Treatment

  • Sulfasalazine

  • Cysteine Hydrochloride

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved